Drug Approval | November 01, 2023
Lupin Mandideep plant gets USFDA green signal
The inspection of the facility conducted from August 7 to August 11, 2023
The inspection of the facility conducted from August 7 to August 11, 2023
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
RHTC will address a long-standing healthcare access issue for all the local population
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Subscribe To Our Newsletter & Stay Updated
